Intelligence · Clinical Development
Pipeline search results
Programs matching “dapagliflozin” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 28 pipeline programs matching "dapagliflozin" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
ANDA219975 + ANDA220011
Lxo Ireland Designated Activity Company
Type 2 Diabetes
1 trial -
D6402C00012
AstraZeneca AB
Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death
1 trial -
D6402C00012
AstraZeneca
Heart Failure and Impaired Kidney Function
1 trial -
DAPA-PedHKD
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pediatric Hereditary Kidney Diseases
1 trial -
DAPAGLIFLOZIN, PLACEBO
Disc Medicine
Hypomagnesemia due to HNF1beta mutation
1 trial -
DAPAGLIFLOZIN, PLACEBO DE DAPAGLIFLOZIN 10 mg
Pari Pharma GmbH
Cardiac failure
1 trial -
Dapagliflozin
AstraZeneca
Type 2 Diabetes
3 trials -
Dapagliflozin
AstraZeneca
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
1 trial -
Dapagliflozin
AstraZeneca
Type 2 Diabetes Mellitus
2 trials -
Dapagliflozin
AstraZeneca
Heart Failure With Preserved Ejection Fraction
1 trial -
Dapagliflozin
AstraZeneca
Heart Failure With Preserved Ejection Fraction (HFpEF)
1 trial -
Dapagliflozin 10 mg
AstraZeneca
Type 2 Diabetes Mellitus
1 trial -
Dapagliflozin 10 mg
AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
1 trial -
METFORMIN , DAPAGLIFLOZIN
Eli Lilly Co.
Type 2 Diabetes
1 trial -
S005201-175
The George Institute
Type 2 Diabetes inadequately controlled with dapagliflozin with or without metformin
1 trial -
D6405C00002
AstraZeneca
Chronic Kidney Disease
1 trial -
Dapagliflozin 10mg Tab
The University of Hong Kong
Lupus Nephritis
1 trial -
dapagliflozin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Acute Kidney Injury
1 trial -
Bioequivalence clinical trial of two formulations of dapagliflozin.
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin
Laboratorios Tillomed Spain S.L.U
Healthy volunteers
1 trial -
The bioavailability study of Dapagliflozin
Laboratorios Tillomed Spain S.L.U
not applicable (submitted trial is a bioequivalence study
1 trial -
Dapagliflozin
AstraZeneca
Diabetes Mellitus, Type 2
1 trial -
Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
The University of Hong Kong
Fontan
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.